Foresite Capital Management Iv, LLC has bought stock on 2 days since May 2023
10% owner at Eikon Therapeutics, Inc., and 1 other company
SEC CIK 0001704132 · Filings on SEC.gov ↗
Foresite Capital Management Iv, LLC's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Companies
Every filing
2 filings since May 2023, newest first
About Foresite Capital Management Iv, LLC
Foresite Capital Management IV, LLC is an investment fund managed by Foresite Capital, a multi-stage healthcare and life sciences investment firm founded in 2011 and headquartered in San Francisco (with offices in Larkspur, California, and New York).( The firm specializes in data- and science-driven investments across seed to public stages, focusing on innovative therapeutics, diagnostics, healthcare technologies, and companies leveraging data science and machine learning to address unmet needs in the $10 trillion global healthcare market; it manages over $2 billion in assets firm-wide, with Fund IV raising $668 million.(
Foresite Capital Management IV, LLC, with CIK 0001704132, holds a portfolio of 6 equity positions valued at approximately $124M to $182M as of its latest Q2 2025 13F filing, including top holdings like Pharvaris N.V., Cytokinetics, and Lyell Immunopharma.( The fund has recently traded as a 10% corporate insider at Eikon Therapeutics, Inc. (EIKN). Foresite Capital is led by founder and CEO Dr. Jim Tananbaum, with a multidisciplinary leadership team including managing directors like Dr. Vik Bajaj, Matt Buten, and others, supported by 27 MDs and PhDs providing technical expertise to portfolio companies.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.